Kythera Claims Kybella Name After Lundbeck Stumbles With Carbella
Executive Summary
FDA initially rejected Kythera's preferred brand name as vulnerable to confusion with the proposed name for Lundbeck's epilepsy treatment, which was delayed by a complete response letter.